Related Experiment Video

Updated: May 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα

Hanna S Radomska1, Meritxell Alberich-Jordà, Britta Will

  • 1Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.

The Journal of Clinical Investigation
|July 17, 2012
PubMed

Insights

Activating mutations in fms-like tyrosine kinase 3 (FLT3) drive leukemia. This study reveals cyclin-dependent kinase 1 (CDK1) inhibition can overcome differentiation block in FLT3-mutated acute myeloid leukemia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Fms-like tyrosine kinase 3 (FLT3) receptor mutations are common in acute myeloid leukemias (AML).
  • FLT3 mutations lead to abnormal activation of downstream signaling pathways, contributing to leukemogenesis.
  • The role of cyclin-dependent kinase 1 (CDK1) in FLT3-mutated AML is not well understood.

Purpose of the Study:

  • To investigate the involvement of the CDK1 pathway in FLT3-mutated AML.
  • To identify novel therapeutic targets for FLT3-mutated AML, particularly those resistant to existing therapies.

Main Methods:

  • Investigated the effect of FLT3 internal tandem duplication (ITD) mutations on CDK1 pathway activity.
  • Identified and characterized C/EBPα as a substrate of CDK1.
  • Assessed the impact of CDK1 phosphorylation on C/EBPα function.
  • Evaluated the therapeutic potential of CDK1 inhibition in FLT3-mutated AML cell lines and primary patient samples.

Main Results:

  • FLT3-ITD mutations affect the CDK1 pathway.
  • CDK1 phosphorylates the granulopoiesis-promoting transcription factor C/EBPα at serine 21, inhibiting its differentiation-inducing function.
  • Inhibition of CDK1 activity restored differentiation in FLT3-mutated AML cell lines and primary patient samples.

Conclusions:

  • The CDK1 pathway plays a critical role in maintaining the differentiation block in FLT3-mutated AML.
  • Targeting CDK1 is a promising therapeutic strategy for FLT3-mutated AML, including FLT3 inhibitor-resistant cases.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.